C4 Therapeutics Inc (CCCC)vsNovartis AG ADR (NVS)
CCCC
C4 Therapeutics Inc
$3.40
+5.76%
HEALTHCARE · Cap: $361.69M
NVS
Novartis AG ADR
$156.08
+3.20%
HEALTHCARE · Cap: $286.29B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 161700% more annual revenue ($56.69B vs $35.04M). NVS leads profitability with a 22.5% profit margin vs -289.4%. NVS earns a higher WallStSmart Score of 51/100 (C-).
CCCC
Avoid28
out of 100
Grade: F
NVS
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+68.2%
Fair Value
$5.75
Current Price
$3.40
$2.35 discount
Margin of Safety
-67.2%
Fair Value
$93.84
Current Price
$156.08
$62.24 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Reasonable price relative to book value
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.6%
Keeps 23 of every $100 in revenue as profit
Generating 5.6B in free cash flow
Areas to Watch
2.8% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : CCCC
The strongest argument for CCCC centers on Debt/Equity, Price/Book.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 34.6%.
Bear Case : CCCC
The primary concerns for CCCC are Revenue Growth, EPS Growth, Market Cap.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Key Dynamics to Monitor
CCCC profiles as a turnaround stock while NVS is a value play — different risk/reward profiles.
CCCC carries more volatility with a beta of 3.08 — expect wider price swings.
CCCC is growing revenue faster at 2.8% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 28/100), backed by strong 22.5% margins. CCCC offers better value entry with a 68.2% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
C4 Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
C4 Therapeutics, Inc., a biopharmaceutical company, develops new therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. The company is headquartered in Watertown, Massachusetts.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?